Maria Berkman

Maria Berkman, MD, MBA


Maria Berkman, MD, MBA, is a Director, and Head of the MedTech practice at Broadview Ventures where she manages the firm’s MedTech investment strategy and activity, from identification and screening of new opportunities through due diligence, negotiation of deal structure, portfolio company board involvement, and overall portfolio strategy.

Maria currently serves on the boards of Alleviant Medical, Aria CV, AtaCor, FineHeart, RapidPulse, Vascular Graft Solutions, and Vectorious Medical Technologies, and previously served on the boards of Lyra Therapeutics (NSDQ:LYRA), Apama Medical (acquired), Remedy Therapeutics (acquired), and Capricor (NSDQ:CAPR).

Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group, where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercial strategy and competitive strategic planning for BioPharma and MedTech clients. Prior to joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned a concurrent MD from the UCLA School of Medicine and MBA from the Anderson School of Management at UCLA, graduating Alpha Omega Alpha.

Outside of Broadview, Maria serves as a VC Mentor for the UCLA Biodesign Fellowship, Life Science Committee member at the Boston Museum of Science, member of the AdvaMed MedTech Investment Working Group, and Co-Chair of the NEVCA MedTech Academy; Maria previously served as an SBIR/STTR grant reviewer for the National Science Foundation and as a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.